[Skip to Content]
[Skip to Content Landing]
February 24, 1997

Drugs and Myasthenia GravisAn Update

Author Affiliations

From the Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy and Science, Philadelphia, Pa.

Arch Intern Med. 1997;157(4):399-408. doi:10.1001/archinte.1997.00440250045006

Myasthenia gravis is a disease of the neuromuscular junction in which normal transmission of the neuron-to-muscle impulse is impaired or prevented by acetylcholine receptor antibodies. Several classes of drugs have been associated with clinical worsening of existing myasthenia gravis, and a small subset of drugs, most notably the antirheumatic agent penicillamine, have been implicated in the pathogenesis of a variant of the disease. Recent case reports and other documented evidence link a number of specific agents with clinical worsening of myasthenia gravis.

Arch Intern Med. 1997;157:399-408